Skip to content

Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using Ultrasound Localization Microscopy

Characterization of Renal Microvascular Alterations in Patients With Active Urinary Sediment and/or Proteinuria Using Ultrasound Localization Microscopy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07469059
Acronym
VARIOUS
Enrollment
30
Registered
2026-03-13
Start date
2025-09-18
Completion date
2028-09-01
Last updated
2026-03-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nephritis

Keywords

kidney, ultrasound localization microscopy (ULM)

Brief summary

The goal of this study is the non-invasive visualization and quantification of renal microvascular dynamics in adult kidneys with proteinuria and/or active sediment.

Detailed description

In this study, the microvascular architecture of the kidney in adults with active urinary sediment or proteinuria is to be examined non-invasively using Ultrasound Localization Microscopy (ULM). Kidney diseases can broadly be classified according to the affected nephron compartment into glomerular, tubular, and tubulointerstitial diseases. Glomerular diseases include, among others, the nephrotic and nephritic syndromes, which differ in their clinical and laboratory characteristics: while the nephrotic syndrome is typically characterized by marked proteinuria (\>3.5 g/day), hypoalbuminemia, edema, and hyperlipidemia, the nephritic syndrome is dominated by hematuria with acanthocytes, mild to moderate proteinuria, arterial hypertension, and impaired renal function. Tubular and tubulointerstitial diseases, on the other hand, often manifest as acute kidney injury (e.g., in ischemic or toxic injury), polyuria, salt wasting, or metabolic acidosis, often accompanied by nonspecific symptoms such as fatigue or dehydration. In addition to these classical nephron compartments, renal vascular structures may also be primarily or secondarily affected, as in vasculitis, thrombotic microangiopathies, or hypertensive nephropathy. Although these vascular structures are not directly part of the nephron, they are functionally closely linked to it and have a significant impact on renal function. To assess kidney status, pathophysiology, and the site of injury non-invasively, urinary sediment is analyzed. Urinary sediment represents a central diagnostic tool that provides information on the localization of kidney damage, thereby functioning as a type of "liquid biopsy." If there is clinical suspicion of acute or rapidly progressive renal failure, nephrotic syndrome, significant non-nephrotic proteinuria, glomerular hematuria, or if a systemic disease with possible renal involvement is present, a kidney biopsy is usually indicated for further diagnostic clarification. Obtaining tissue samples for histological examination is an invasive procedure associated with inpatient hospitalization, considerable burden for patients, and potential complications. Currently, alternative imaging methods cannot replace kidney biopsy. Furthermore, CT, PET, or MR imaging is associated with radiation exposure or considerable additional effort (e.g., sedation). Ultrasound Localization Microscopy (ULM) enables visualization of vascular architecture using contrast-enhanced ultrasound. Recently, glomeruli-the smallest functional units of the kidney-were visualized and even counted in both rats and humans. Thus, ULM enables an assessment of renal function potentially comparable to kidney biopsy, in which glomeruli are also counted and examined. Beyond the kidney, the microvascular architecture of the human brain has also been depicted at previously unknown resolution using ULM. ULM therefore offers both qualitative and quantitative visualization of vascular architecture and perfusion dynamics. In the latest studies, 3D ULM imaging has been achieved, allowing volumetric visualization of vascular architecture and thereby overcoming the limitations of 2D imaging. This three-dimensional depiction of vascular structures may potentially provide more realistic insights into disease-related changes that would otherwise not be possible. In the following, the term 'ULM' is used inclusively for both 2D and 3D ULM. In this study, renal function and perfusion in patients with active urinary sediment and indication for kidney biopsy will be evaluated, compared, and correlated with results from histology (biopsy), laboratory tests, and ultrasound diagnostics. If possible, a follow up assessment via ULM/CEUS after treatment (for example pharmacological therapy) will be scheduled. With ULM the investigators aim to visualize the microvascular architecture and glomeruli, and to investigate whether differences detectable by ULM can be identified for the various causes of active sediment. In addition, the investigators seek to establish alterations in perfusion dynamics as potential imaging markers of kidney function. In the future, this could enable non-invasive differentiation of the underlying disease and assessment of renal function, potentially reducing the need for invasive, high-risk procedures and allowing faster diagnosis in patients with an indication for kidney biopsy due to active sediment or proteinuria.

Interventions

None listed

Sponsors

University of Erlangen-Nürnberg Medical School
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Evidence of active urinary sediment and/or proteinuria \>1 g/g creatinine * Indication for kidney biopsy as part of study-independent diagnostics * Written informed consent

Exclusion criteria

* Known allergic disposition to SonoVue® * Contraindication to the use of SonoVue® * Pregnancy * Breastfeeding mothers

Design outcomes

Primary

MeasureTime frameDescription
CEUS Time intensity curvesbaseline and up to 10 weeks after baselineAll CEUS outcomes will be generated in order to achieve time intensity curves in contrast enhanced ultrasound analysis
CEUS Measurement1baseline and up to 10 weeks after baselinePE (Peak-Enhancement) is an established measurement in CEUS analysis. It describes the highest signal intensity after administration of contrast agents and is measured in arbitrary units. All CEUS measurements are established measurements in Time intensity analysis (TIC) of contrast enhanced ultrasound data.
CEUS Measurement2Baseline and up to 10 weeks after baselineDescription: WiAUC (Wash-in Area Under the Curve (AUC(TI: TTP)))
CEUS Measurement 3Baseline and up to 10 weeks after baselineRT (Rise Time = arterial inflow until maximum signal intensity), measured in seconds, higer RT means faster arterial inflow
CEUS Measurement5Baseline and up to 10 weeks after baselinemTT (mean Transit Time local) (mTT-TI))
CEUS Measurement6Baseline and up to 10 weeks after baselineTTP (Time to Peak)
CEUS Measurement7Baseline and up to 10 weeks after baselineWiR (Wash-in-Rate )
CEUS Measurement8Baseline and up to 10 weeks after baselineWiPI (Wash-in Perfusion Index (WiAUC/RT))
CEUS Measurement9Baseline and up to 10 weeks after baselineWoAUC (Wash-out AUC (AUC(TTP:TO)))
CEUS Measurement10Baseline and up to 10 weeks after baselineWiWoAUC (Wash-in- und Wash-out-AUC (WiAUC+WoAUC))
CEUS Measurement11Baseline and up to 10 weeks after baselineFT (Fall Time - (TO-TTP))
CEUS Measurement12Baseline and up to 10 weeks after baselineWOR (Wash-out-Rate) QOF (Quality Of Fit between the echo-power signal and f(t)
CEUS Measurement13Baseline and up to 10 weeks after baselineQOF (Quality Of Fit between the echo-power signal and f(t)
Visualization and quantification of kidney perfusion with CEUSBaseline and up to 10 weeks after baselineCEUS imaging for kidney perfusion in kidney disease
Visualization and quantification of kidney mikrovaskularisation with ULMBaseline and up to 10 weeks after baselineULM imaging for kidney perfusion and microvaskularisation in kidney disease
Visualization and quantification of glomeruli in the kidney with ULMBaseline and up to 10 weeks after baselineULM imaging for glomeruli in the kidney

Secondary

MeasureTime frameDescription
ULM and UltrasoundBaseline and up to 10 weeks after baselineCorrelation of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (e.g., number of segmented glomeruli) with sonographic parameters (including resistance index a.o.)
ULM and CEUSBaseline and up to 10 weeks after baselineCorrelation of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (e.g., number of segmented glomeruli) with parameters of contrast-enhanced ultrasound (CEUS)
ULM and biopsyBaseline and up to 10 weeks after baselineCorrelation of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (including the number of segmented glomeruli) with histological parameters.
2D and 3D ULMBaseline and up to 10 weeks after baselineComparison of visualized and quantified microvascular dynamics (including glomeruli) using 2D and 3D ULM
ULM and diagnosisBaseline and up to 10 weeks after baselineComparison of the vascular architecture visualized by ULM (including the number of segmented glomeruli) with the underlying diagnosis in patients with active sediment and/or proteinuria \>1 g/g creatinine and indication for kidney biopsy.
Comparison before and after treatmentBaseline and up to 10 weeks after baselineComparison of microvascular dynamics via ULM/CEUS in the kidney before and after treatment (e.g., pharmacological therapy)
Correlation between ULM and laboratory parametersBaseline and up to 10 weeks after baselineCorrelation of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (e.g., number of segmented glomeruli) with laboratory parameters (including kidney function parameters, inflammatory markers, immunological parameters.
ULM on different diagnosesBaseline and up to 10 weeks after baselineComparison of the vascular architecture visualized by ULM and parameters of quantified microvascular perfusion dynamics of the kidney (e.g., number of segmented glomeruli) between different diagnoses.
Assessment of renal function GFRBaseline and up to 10 weeks after baselineGFR (ml/min/1,73 m2)
Assessment of renal function ureaBaseline and up to 10 weeks after baselineurea (mg/dl)

Countries

Germany

Contacts

CONTACTFerdinand Knieling, MD, PhD, MHBA
ferdinand.knieling@uk-erlangen.de091318533118
CONTACTHenriette Mandelbaum, MD, PhD
henriette.mandelbaum@uk-erlangen.de09131 85 33118

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 14, 2026